GNLX

GENELUX Corp

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001231457 Biotech & Drug Discovery

$1.91 −0.09 (−4.50%)

Oct 26 4:00 PM ET · prev $2.00

Market cap

$89.6M

Micro cap

Median target

$17.00

+790% · range $12.00–31.00

Next earnings

Nov 2

in 7 days · EPS est. −$0.20

1 year

−73.8%

from $7.30 · Oct 27

30 days

−22.7%

from $2.47

52-week range

$1.91–8.24

at the low

Avg volume 20D

369.2K

Oct 22 spike 947.4K

Short interest

4.36M

≈9.6% of shares · +6.5%

Days to cover

20.4

at average volume

Insider net

−$280.8K

0 buyers · 6 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 2 reports · 90 days

Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score

Avg score

·Next Earnings date, Nov 2, 2026

Strongest BEARISH Three top executives at GENELUX Corp — the CEO, CSO, and CTO — sold a combined $147K in open-market sales on…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 19 Genelux reported its 2025 financial results, showing a narrowed net…
S Mar 24 to Mar 25 2 days of insider sells: $14.5K by 4 insiders, avg $2.42
S May 11 4 insiders sell $12.6K at $2.95
S Jun 1 to Jun 3 2 days of insider sells: $30.4K by 2 insiders, avg $2.98
S Jul 1 1 insider sell $34.9K at $2.91
S Aug 4 3 insiders sell $12.8K at $2.95
S Aug 31 3 insiders sell $146.7K at $2.70
E Sep 9 FDA: Genelux Announces Publication of a Deep and Durable Respon…

Signal stack

Where each data set points today.

InsidersBEARISH

6 insiders sold $280.8K.
InstitutionsMIXED

Q2 2026: 5 added (0 new), 6 trimmed or exited.
EstimatesRISING

Current-quarter EPS estimate −$0.203 → −$0.198 over 90 days. 2 up, 1 down in 30 days.
Short sellersSTEADY

Short interest +6.5% to 4.36M shares. 20.4 days to cover, ≈9.6% of shares.
TrendDOWNTREND

24% below its 50-day average. New closing low $1.91 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
ROYAL BANK OF CANADA	DOUBLED	213	—
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	105,229	$316.7K
NORTHERN TRUST CORP	TRIM	89,279	$268.7K
Mariner, LLC	ADD	52,866	$159.1K
GOLDMAN SACHS GROUP INC	ADD	45,809	$137.9K
UBS Group AG	TRIM	34,995	$105.3K
HRT FINANCIAL LP	DOUBLED	33,379	$100.0K
Hudson Bay Capital Management LP	TRIM	21,542	$64.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026

12-month targets · 6 analysts

$1.91 $12.00 $17.00 $31.00

Price is below the lowest target. Median implies +790%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Mar 20, 2026	Benchmark MAINTAIN	MAINTAIN	Speculative Buy
Oct 21, 2025	Lake Street INITIATE	INITIATE	Buy
Jul 21, 2025	LUCID CAPITAL MARKETS INITIATE	INITIATE	Buy
May 8, 2025	Benchmark MAINTAIN	MAINTAIN	Speculative Buy
Mar 31, 2025	HC Wainwright & Co. REITERATE	REITERATE	Buy
Mar 25, 2025	HC Wainwright & Co. REITERATE	REITERATE	Buy

Insider ledger

Form 4

bought · 0 insiders

$280.8K

sold · 6 insiders

Date	Insider	Type	Value
Aug 31, 2026	Yu Yong Chief Scientific Officer	SELL	$26.7K
Aug 31, 2026	Zindrick Thomas President and CEO	SELL	$91.9K
Aug 31, 2026	Cappello Joseph Chief Technical Officer	SELL	$28.1K
Aug 4, 2026	Yu Yong Chief Scientific Officer	SELL	$1.9K
Aug 4, 2026	Cappello Joseph Chief Technical Officer	SELL	$1.9K
Aug 4, 2026	Zindrick Thomas President and CEO	SELL	$8.9K
Jul 1, 2026	Smither John W Director	SELL	$34.9K
Jun 16, 2026	Pulisic Matthew Chief Financial Officer	AWARD	278,906 sh

Earnings setup

Estimates

Nov 2

reports in 7 days

−$0.20

EPS estimate, this quarter

+2%

estimate change, 90 days

2↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.203

90d

−$0.203

60d

−$0.202

30d

−$0.194

−$0.198

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.20	-$0.22–-$0.18	+1.7%	$0.00
Next Q	-$0.20	-$0.23–-$0.17	+2.4%	$0.00
Current FY	-$0.81	-$0.86–-$0.77	+0.2%	$0.00
Next FY	-$0.75	-$0.92–-$0.56	-0.2%	$7.8M

Short side

FINRA· Sep 30, 2026

4,362,110

shares short

+6.5%

vs prior settlement

20.4

days to cover

≈9.6%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Sep 9, 2026 FDA

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy

-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Ve

Sep 2, 2026 SEC

Three top executives at GENELUX Corp — the CEO, CSO, and CTO — sold a combined $147K in open-market sales on August…

CLUSTER — Impact 5/10

Aug 31, 2026 Insider

Yu Yong sold 9,683 shares

Chief Scientific Officer @ $2.75 ($26.7K)

Aug 31, 2026 Insider

Zindrick Thomas sold 34,463 shares

President and CEO @ $2.67 ($91.9K)

Aug 31, 2026 Insider

Cappello Joseph sold 10,257 shares